In a report published on August 14, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Vical (NASDAQ: VICL [FREE Stock Trend Analysis]), but lowered the price target from $6.00 to $3.00.
In the report, Citigroup noted, “We remain long-term buyers of VICL but are lowering our target price to $3 (-$3), representing an almost doubling of the current share price. While the failure of the Ph3 melanoma trial is a clear disappointment, we have consistently seen value in VICL's remaining pipeline. We note a remaining $95M in milestones from the ASP0113 (TransVax) program with Astellas, the large market and industry focus on the preventative CMV market for women of child-bearing age, potential market for VICL's genital herpes vaccine, and the scarcity value for the company's potent and unencumbered vaccine adjuvant Vaxfectin.”
I would be very hesitant to purchase any Vical at this time. The company has not performed well, has a CEO that is despised by many, and the share price has retreated to historic lows with no analytical evidence for it to recover in the near future. The cash reserves will not last forever and if Vical does not find another partner or have significant success in the next trial, the bankruptcy that has been discussed will be more likely.
Sentiment: Strong Sell
Jonathan Eckard does not know near as much about VICL as James Singer does. He has the inside scoop on what will happen when the herpes vaccine does not perform as expected. Look what happened after the Allovectin failure. I could not recommend VICL to anyone I care about because their performance has been substandard for years. VJ is doing a horrible job and is vastly overpaid. Investors have lost confidence and shares have been flying out at lower prices for the past several weeks. VICL cannot count on dumb investors and the general public now knows that the same researchers who failed with Allovecting are working on the herpes vaccine. At least the ones who are left after the significant layoffs made a few weeks ago. VICL is selling for less than it did 20 YEARS ago. If the herpes vaccine is not succesful, you may get your wish, but only after VICL goes through a bankruptcy and reorganization with the hope of not being delisted. Spare me the bit about their cash reserves because those will dry up quickly. I wish there were better news, but there simply is not at this time. Get out while you can and invest in ISIS.
Totally agree. That's why some stupidos have been hanging on this one tree forever, they will stay till they lose all while other real investors are making $$$ somewhere else... :):)
Sentiment: Strong Sell
During the last months of 2012, Marxe Austin sold some million shares of INO (Inovio) around $0.50, while a few analysts (less reliable than J. Eckard) gave much higher target prices, above $1.
Today, INO is traded above $2.
Obviously, the insider was wrong...there is many reasons to sell, by only one to buy. Don't count to much to J. Singer's trades.
The latest price target from 4 traders:
Mean consensus OUTPERFORM
# of Analysts 7
average target price 3,88 $
Last Close Price 1,26 $
Spread / Highest target 456%
Spread / Average Target 208%
Spread / Lowest Target 11%
BELOW IS EXCERPT FROM A-7 ANNOUNCEMENT COVERAGE. VICAL'S PIPELINE IS NOT TRUSTED BECAUSE VIJAY IS NOT TRUSTED AND SINCE HE STILL HAS A JOB THE BOARD IS NOT TRUSTED. VICAL NEEDS TO BE SOLD TO A REPUTABLE COMPANY NOW!
Chief Executive Officer Vijay Samant said Allovectin failed to show “statistically significant improvement” in the study of 390 patients with metastatic melanoma. The company had cash and investments of $70 million as of June 30, enough to meet its needs through the end of next year, according to the statement.
“In the coming weeks, we will make the necessary changes to focus resources on our infectious disease vaccine programs and reduce expenses to conserve cash,” Samant said in the statement.
Vical shares had risen 23 percent this year through Aug. 9.
While the company is testing other drugs, it faces “a lack of confidence in Vical’s pipeline candidates and a frustration with the slow pace at which Vical’s DNA-based gene delivery platform has advanced,” Eric Schmidt, a Cowen & Co. analyst in New York, said today in a note to clients.
i copied the words "Citigroup analyst Jonathan Eckard reiterated a Buy rating on Vical" and entered into google and found the original like. just to let everyone know that this is, indeed, authentic.
thanks for the info'
Here is some additional information regarding VICL's target price from various analysts.
A number of research firms have recently commented on VICL. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Vical (NASDAQ:VICL) in a research note to investors on Wednesday, August 14th. They now have a $3.00 price target on the stock, down previously from $6.00. Separately, analysts at Credit Suisse downgraded shares of Vical (NASDAQ:VICL) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 13th. They now have a $2.00 price target on the stock, down previously from $5.00. Finally, analysts at Stifel Nicolaus downgraded shares of Vical (NASDAQ:VICL) from a “buy” rating to a “hold” rating in a research note to investors on Monday, August 12th.
Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $3.35.